In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous
recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in
patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA
given in the early hours of acute myocardial infarction should be followed by percutaneous
transluminal coronary angioplasty (PTCA).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Plasminogen Tissue Plasminogen Activator
Criteria
Men and women under age 76. Patients had acute myocardial infarction.